Safety Study of a Fluorescent Marker to Visualize Cancer Cells

NCT ID: NCT02097875

Last Updated: 2015-04-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 21 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-12-31
• Study Completion Date: 2015-03-31

Brief Summary

Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed. It is often difficult for surgeons to distinguish tumor tissue from normal tissue or to detect tumor cells that have spread from the original tumor site, resulting in incomplete removal of the tumor and reduced patient survival. In addition, in some sites, such as the brain, it is critical to avoid damage to normal tissue around the tumor to prevent adverse effects of surgery on function. We hypothesize that BLZ-100 will improve surgical outcomes by allowing surgeons to visualize the edges of the tumor and small groups of cancer cells that have spread to other sites in real-time, as they operate.

Conditions

Skin Neoplasms

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BLZ-100

A single dose of BLZ-100 (1, 3, 6, 12 or 18 mg) will be administered by intravenous injection approximately 48 hours prior to planned excision of skin tumor.

Group Type: EXPERIMENTAL

BLZ-100

Intervention Type: DRUG

Interventions

BLZ-100

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Male or female patients age ≥ 18 years.
• Known or suspected non-metastatic basal cell or squamous cell carcinomas ≥10 mm longest diameter or non-metastatic melanoma ≥6 mm longest diameter scheduled for excision, without advanced disease.
• Written Informed Consent.
• Agree to the use of effective contraceptive from Baseline and for 30 days after treatment if either male or female of child bearing potential.
• Available for and able to comply with study requirements.

Exclusion Criteria

• Women who are lactating/breastfeeding
• Women with a positive pregnancy test or who are planning to become pregnant during the duration of the study.
• Life expectancy <6 months.
• Karnofsky Performance Status of ≤70%.
• The following laboratory abnormalities:

• Neutrophil count <1.5 x 10^9/L
• Platelets <75 x 10^9/L
• Haemoglobin <10 g/dL (may be determined following transfusion)
• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2x upper limit of normal (ULN)
• Total bilirubin >2x upper limit of reference range (unless Gilbert's syndrome or extrahepatic source as denoted by increased indirect bilirubin fraction)
• International Normalized Ratio (INR) >1.5
• Creatinine >1.5x ULN
• History of hypersensitivity or allergic reactions requiring corticosteroids, epinephrine and/or hospitalization.
• Uncontrolled asthma or asthma requiring oral corticosteroids.
• Clinically significant chronic inflammatory skin conditions, including psoriasis, atopic dermatitis and scleroderma, as determined by the investigator.
• Unstable angina, myocardial infarction, known or suspected transient ischemic events or stroke within 24 weeks of Screening.
• Uncontrolled hypertension.
• QTc (corrected QT interval) prolongation >450 msec.
• Receipt of photosensitising drugs within 30 days of screening.
• Positive serology for human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV).
• Any concurrent condition, including psychological and social situations, which, in the opinion of the investigator, would impact adversely on the subject or the interpretation of the study data.
• Known or suspected sensitivity to study product or excipients.
• Prior participation in this clinical trial (has received study product).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Blaze Bioscience Australia Pty Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Lynda Spelman, MBBS FACD

Role: PRINCIPAL_INVESTIGATOR

Veracity Clinical Research Pty Ltd

Locations

Veracity Clinical Research Pty Ltd

Woolloongabba, Queensland, Australia

Countries

Australia

References

Yamada M, Miller DM, Lowe M, Rowe C, Wood D, Soyer HP, Byrnes-Blake K, Parrish-Novak J, Ishak L, Olson JM, Brandt G, Griffin P, Spelman L, Prow TW. A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients. Contemp Clin Trials Commun. 2021 Aug 4;23:100830. doi: 10.1016/j.conctc.2021.100830. eCollection 2021 Sep.

Reference Type: DERIVED

PMID: 34401600 (View on PubMed)

Other Identifiers

ACTRN12614000115639

Identifier Type: REGISTRY

Identifier Source: secondary_id

BB-001

Identifier Type: -

Identifier Source: org_study_id